BioWorld MedTech

Nov. 3, 2011

Mela Sciences secures PMA for MelaFind after lengthy delays

Mela Sciences (Irvington, New York) reported that it has received a PMA for its MelaFind skin cancer detection device, after intense discussion with the FDA regarding the device throughout the past few years. Read More

VitroStealth shows potential as a coating for biosensors

International report: CoreValve system used for first time in Japanese clinical trial

Washington roundup: CMS announces 27% pay cut for Part B doc fees in FY '12

Financings roundup: Echo says warrant deal offers financial flexibility

Patent watch: Biomoda files application for CyPath refinement tool

Late-Breaking FDA valve stent approvals: Edwards gets FDA approval for Sapien transcather valve

FDA approves TriVascular's 20-mm Ovation stent system

NASS Notebook: Orthofix launches Collage bone graft substitute at NASS

Court report: MRI Associates awarded $52M in damages in case

HIT roundup: Trend renews membership with MDISS consortium

Agreements/contracts: Welch Allyn to provide EHR services to organizations

Deals roundup: Salmat's management buyout of VeCommerce is complete

Product Briefs

People in the News

MDD's Ortho Extra

Today's news in brief

BioWorld

BioWorld briefs for July 17, 2026.

AI-generated illustration of a neuron with tau protein aggregation

AAIC 2026: Age of amyloid is being joined by time of tau

BioWorld

The Alzheimer’s Association International Conference (AAIC) is the world’s biggest dementia conference. And at the AAIC 2026 meeting, there is big buzz around...

Celia trial: data strong, analysts skeptical

BioWorld

Tuesday brought what was arguably the most anticipated presentation of the 2026 Alzheimer’s Association International Conference when Catherine Mummery, head of...

News in brief

BioWorld Asia

BioWorld Asia briefs for July 14, 2026

Voyager’s gene therapy reduces tau levels in AD models

BioWorld Science

At the Alzheimer’s Association International Conference, researchers from Voyager Therapeutics Inc. presented preclinical efficacy data for VY-1706, a blood-brain...